Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019001349
Abstract: In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or older (median age, 68 years) were prospectively enrolled… read more here.
Keywords: risk; gene mutations; intermediate risk; alfa 1200 ... See more keywords
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006689
Abstract: Outcomes of older and un fi t adults with acute myeloid leukemia (AML) differ signi fi cantly from their younger counterparts, owing to their adverse disease biology (complex karyotype, antecedent myelo-dysplastic syndrome) and age-related comorbidities.… read more here.
Keywords: double nucleoside; alfa 1200; patients aml; therapy ... See more keywords